QSV Biologics has been awarded a cGMP manufacturing contract for a recombinant protein under development by Pfizer. The protein, intended for clinical trials, will be manufactured at QSV’s Edmonton facility in Canada. The project, to begin immediately, will include technology transfer, scale-up and cGMP manufacturing.
   
Graeme Macaloney Ph.D., P.Eng., founder, president and chief executive officer of QSV, said, “We are extremely pleased and honored that Pfizer has chosen QSV Biologics from a strong field of contending CMOs as their manufacturing partner for this project. The execution of this contract is the culmination of extended evaluations by the Pfizer organization, reflecting QSV’s continuing dedication to quality, speed and value. This project is an extremely good fit for our capabilities and indicative of our ability to respond to the challenging requirements of respected companies like Pfizer.”
   
“Pfizer is pleased to engage QSV for the clinical manufacturing of a complex biotechnology product,” said Rick Rutter, Ph.D., vice president of Global Biologics in the Pharmaceutical Sciences division of Pfizer Global R&D. “Speed to clinic is of great importance for early development candidates and QSV has a record of delivering quality product on-time and on-budget. QSV will play a supporting role in realizing Pfizer’s vision of becoming a top-tier biotherapeutic company.”